• Epirubicin;
  • superficial bladder cancer;
  • chemoresectin;
  • response

Objective To determine the response of a marker tumour to a single instillation of intravesical epirubicin.

Patients and methods Eighty-one patients (54 men, 27 women) with a mean age of 69.3 years (range 36–92) with superficial bladder cancer were randomized to receive a single instillation of intravesical epirubicin. At the initial cystoscopy all but one papillary marker tumour was resected. Subsequently the patients were a randomized to receive either intravesical epirubicin at a concentration of 1 mg/ml (n=40) or 2 mg/ml (n=41) in 50 ml of saline for 1h. THe response of the marker tumour was determined at 3 months (first check cystoscopy). The toxicity associated with both treatments was also recorded.

Results A complete response (no visible or microscopic bladder carcinoma) was observed in 46% (95% confidence interval (CI) 35–57%) of a patients. No patient experienced systemic side-effects. Chemical cystitis and bladder irritability were the most frequent local sideeffects, occurring in 15% (95% CI 8 - 24%) of the patients.

Conclusions A single instillation of intravesical epirubicin has a demonstrable effect in superficial bladder cancer. The results compare farvourably with more onerous regimes. Side-effects were minimal at 1 mg/ml and acceptable at 2 mg/ml.